Zufall Health Welcomes Penn Medicine Princeton Health’s Noah Goldman, MD, MBA to Board of Directors
Zufall Health announced that Noah Goldman, MD, MBA, medical director of cancer programs at Penn Medicine Princeton Health, has joined its Board of Directors.
A gynecologic oncology specialist with more than 25 years of experience, Goldman has led Princeton Health’s comprehensive oncology programs since 2021. In addition to seeing patients, he collaborates with administrative and medical leadership to ensure quality care and advance innovative cancer treatments.
Goldman also serves on the faculty of Albert Einstein College of Medicine, New York University School of Medicine, Columbia University, and Mount Sinai Hospital.
“We are so pleased to welcome Dr. Goldman’s clinical, academic, and administrative expertise to our diverse Board of Directors,” said Fran Palm, president and CEO of Zufall Health. “Both gynecological care and cancer prevention are key priorities for our patients, and Dr. Goldman’s expertise will be invaluable as we work to expand access to these and other critical services across primary care. His Board service will also help us nurture our ongoing successful collaboration with Penn Medicine Princeton Health.”
Since 2021, Zufall has provided quality and affordable medical and behavioral health services in a spacious, 21-exam room facility on the Princeton Health campus. In 2024, with funding from the hospital, Zufall added dental services to the site.
“I am so impressed by Zufall’s contributions to the Plainsboro community in such a short time, and I am honored to join its Board of Directors,” said Goldman. “I look forward to supporting the health center’s efforts to bring essential primary and preventive care to underserved populations in Middlesex County and beyond.”
Board-certified in gynecologic oncology and obstetrics and gynecology, Goldman earned a doctor of medicine degree from the former University of Medicine and Dentistry of New Jersey, now Rutgers University, and a bachelor’s degree in biochemistry from University of Rochester. He completed an Executive MBA from Rutgers University.